Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 27, 2026

Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making

View original at finance.yahoo.com
Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making DelveInsight provides structured pharma conference coverage solutions designed to help industry leaders to track and interpret critical developments emerging from major healthcare conferences…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DelveInsight is a leading provider of strategic conference coverage solutions, specializing in tracking, analyzing, and summarizing insights from global healthcare and pharmaceutical events across multiple therapy areas

    80% confidence

  • DelveInsight is a pioneer in providing customized conference coverage services, supporting client needs across indication and therapy area monitoring, inhibitor-specific updates, booth intelligence, KOL insights, phase transitions, and post-conference summaries

    80% confidence

  • The pharmaceutical sector continues to evolve at an unprecedented pace, and missing a pivotal presentation could mean missing emerging efficacy trends, novel mechanisms, or competitor signals shaping tomorrow's market

    80% confidence

  • Clients can track multiple conferences throughout the year under a single therapeutic area, such as Oncology, ensuring continuous year-round competitive and scientific intelligence

    80% confidence

  • DelveInsight's competitive intelligence services equip clients with real-time, accurate insights spanning multiple therapeutic domains including competitor pipelines, clinical trial tracking, gene and cell therapy innovations, market-entry strategies, and regulatory and patent landscapes

    80% confidence

  • In the rare disease space, DelveInsight monitors global R&D progress, competitive developments, and shifting regulatory landscapes to provide tailored insights that guide product positioning and investment strategies

    80% confidence

  • DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences

    80% confidence

  • DelveInsight's conference coverage spans major therapeutic areas from oncology to rare disease, annually covering major conferences such as ASCO, ESMO, ASH, AACR, ATS, ERS, etc.

    80% confidence

Cited in these Via News reports